---
title: Building manufacturing processes for reproducible, multi-yeariPSC-based drug screening
description: Ncardia’s innovative iPSC-based platform for ALS drug screening using motor neuron assays, high-content imaging, and electrophysiological characterization to support predictive therapeutic evaluation.
---

[Resources ](https://www.ncardia.com/insights/resources)

# [Building manufacturing processes for reproducible, multi-yeariPSC-based drug screening](https://www.ncardia.com/insights/resources/building-manufacturing-processes-for-reproducible-multi-yearipsc-based-drug-screening-clone)

 Written by [Ncardia Stem Cell Experts](https://www.ncardia.com/insights/resources/author/ncardia) | February 17, 2026

This poster presents Ncardia’s human iPSC-based platform for modeling and screening amyotrophic lateral sclerosis, built around disease-relevant motor neuron assays that capture key pathological hallmarks of TDP-43 dysfunction.

Download it now for a closer look at:

- How CRISPR-engineered TDP-43 mutant motor neurons reproduce core ALS phenotypes, including TDP-43 mislocalization, aggregation, STMN2 reduction and mis-splicing.
- High-content imaging and miniaturized assay formats that enable quantitative, scalable assessment of protein aggregation and molecular rescue.
- Electrophysiological characterization by MEA, demonstrating altered network activity and functional deficits in mutant motor neurons.
- Proof-of-concept data showing successful transduction and therapeutic rescue, including significant reduction of TDP-43 aggregation and improvement of functional readouts.
- Why integrating molecular, imaging, and functional endpoints in a single human-relevant platform supports more predictive evaluation of ALS therapeutic candidates.

[ Download the Poster ](https://www.ncardia.com/insights/resources/building-manufacturing-processes-for-reproducible-multi-yearipsc-based-drug-screening-clone?hs_amp=true#download-resource)

[View full post](https://www.ncardia.com/insights/resources/building-manufacturing-processes-for-reproducible-multi-yearipsc-based-drug-screening-clone)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Ncardia Stem Cell Experts"
  },
  "dateModified" : "2026-03-10T09:00:29.230Z",
  "datePublished" : "2026-02-17T15:08:01Z",
  "headline" : "Building manufacturing processes for reproducible, multi-yeariPSC-based drug screening",
  "image" : {
    "@type" : "ImageObject",
    "height" : 1189,
    "url" : "https://25505018.fs1.hubspotusercontent-eu1.net/hubfs/25505018/Drugs_screening_poster_SLAS_2026.png",
    "width" : 841
  },
  "mainEntityOfPage" : "https://www.ncardia.com/insights/resources/building-manufacturing-processes-for-reproducible-multi-yearipsc-based-drug-screening-clone",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Resources"
  }
}
```